Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
EU Okays CV Benefit Labeling for Canagliflozin in DiabetesThe European label for the SGLT2 inhibitor canagliflozin for type 2 diabetes will now include positive cardiovascular benefit results from the CANVAS trial, while a decision from the US FDA is forthcoming.
